Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa

Cancer Investigation

Volumn 20, Issue 5-6, 2002, Pages 759-768

  Mitchell, Malcolm S ^a   Darrah, Denise ^a   Stevenson, Lucy ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MELACINE; RECOMBINANT ALPHA2B INTERFERON; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOSKELETON PROTEIN; DETOX ADJUVANT; DRUG DERIVATIVE; LIPID A;

ADVANCED CANCER; ALLOGRAFT; CELL LYSATE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DISSEMINATED CANCER; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MELANOMA; MYCOBACTERIUM PHLEI; PRIORITY JOURNAL; RELAPSE; SUPPRESSOR CELL; SURVIVAL TIME; TUMOR LOCALIZATION; CELL CULTURE; DRUG COMBINATION; METASTASIS; MULTICENTER STUDY; PATHOLOGY; REVIEW; SKIN TUMOR; SURVIVAL;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS; CYTOSKELETAL PROTEINS; DRUG COMBINATIONS; HUMANS; INTERFERON-ALPHA; LIPID A; MELANOMA; MULTICENTER STUDIES; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0036048115     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120002493     Document Type: Conference Paper

References (21)

1. Mitchell, M.S.; Kan-Mitchell, J.; Kempf, R.A.; Harel, W.; Shau, H.; Lind, S. Active Specific Immunotherapy of Melanoma, Phase I Trial of Allogeneic Melanoma Lysates and a Novel Adjuvant. Cancer Res, 1988, 48, 5883-5893.
2. Mitchell, M.S.; Harel, W.; Kempf, R.A.; Kan-Mitchell, J.; Boswell, W.D.; Hu, E.; Dean, G.; Stevenson, L. Active-Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1990, 8, 856-869.
3. Berd, D.; Maguire, H.J.; Mastrangelo, M.J. Potentiation of Human Cell-Mediated and Humoral Immunity by Low-Dose Cyclophosphamide. Cancer Res. 1984, 44, 5439-5443.
4. Morton, D.L.; Foshag, L.J.; Hoon, D.S.; Nizze, J.A.; Famatiga, E.; Wanek, L.A.; Chang, C.; Davtyan, D.G.; Gupta, R.K.; Elashoff, R. Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine [Published Erratum Appears in Ann. Surg. 1993 Mar; 217(3):309]. Ann. Surg. 1992, 216, 463-482.
5. Mitchell, M.S.; Jakowatz, J.; Harel, W.; Dean, G.; Stevenson, L.; Boswell, W.D.; Groshen, S. Increased Effectiveness of Interferon-alfa 2b Following Active Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1994, 12, 402-411.
6. Elliott, G.T.; McLeod, R.A.; Perez, J.; Von Eschen, K.B. Interim Results of a Phase II Multicenter Clinical Trial Evaluating the Activity of a Therapeutic Melanoma Vaccine (Theraccine) in the Treatment of Disseminated Malignant Melanoma. Semin. Surg. Oncol. 1993, 9, 264-272.
7. Hersey, P. Vaccinia Viral Lysates in Treatment of Melanoma. In Biological Approaches to Cancer Treatment: Biomodulation; Mitchell, M.S., Ed.; McGraw-Hill: New York, 1992; 302-325.
8. Kirkwood, J.M.; Ernstoff, M.E. Potential Applications of the Interferons in Oncology. Semin. Oncol. 1986, 13, 48-56.
9. Mitchell, M.S. Perspective on Allogeneic Melanoma Lysates in Active Specific Immunotherapy. Semin. Oncol. 1998, 25, 623-635.
10. Mitchell, M.S.; Harel, W.; Kempf, R.A.; Kan-Mitchell, J.; Boswell, W.D.; Hu, E.; Dean, G.; Stevenson, L. Active-Specific Immunotherapy for Melanoma. J. Clin. Oncol. 1990, 8, 856-869.
11. Mitchell, M.S.; Harel, W.; Kan-Mitchell, J.; LeMay, L.G.; Goedegebuure, P.; Huang, X.-Q.; Hofman, F.; Groshen, S. Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates: Rationale, Results and Possible Mechanisms of Action. In Specific Immunotherapy of Cancer with Vaccines; Bystryn, J.-C., Ferrone, S., Livingston, P., Eds.; Ann. N.Y. Acad. Sci., 1993; 153-166.
12. Kan-Mitchell, J.; Huang, X.-Q.; Steinman, L.; Oksenberg, J.R.; Harel, W. ; Parker, J.W.; Goedegebuure, P.; Darrow, T.L.; Mitchell, M.S. Clonal Analysis of In Vitro-Activated CD8 + Cytotoxic T Lymphocytes from a Melanoma Patient Responsive to Active Specific Immunotherapy. Cancer Immunol. Immunother. 1993, 37, 15-25.
13. Huang, X.-Q.; Mitchell, M.S.; Liggett, P.E,; Murphree, A.L.; Kan-Mitchell, J. Non-fastidious, Melanoma-Specific CD8 + Cytotoxic T Lymphocytes from Choroidal Melanoma Patients. Cancer Immunol. Immunother. 1994, 38, 399-405.
14. LeMay, L.G.; Kan-Mitchell, J.; Goedegebuure, P.; Harel, W.; Mitchell, M.S. Detection of Human Melanoma-Reactive CD4 + HLA Class I-Restricted Cytotoxic T Cell Clones with Long-Term Assay and Pretreatment of Targets with Interferon-Gamma. Cancer Immunol. Immunother. 1993, 37, 187-194.
15. Goedegebuure, P.; Harel, W.; LeMay, L.G.; Kan-Mitchell, J.; Mitchell, M.S. Cytotoxic CD4 + Lymphocyte Clones Reactive with Melanoma: The Role of HLA and Accessory Molecules. Vaccine Res. 1994, 2, 249-261.
16. Mitchell, M.S.; Harel, W.; Groshen, S. Association of HLA Phenotype with Clinical Response to Active Specific Immunotherapy of Melanoma. J. Clin. Oncol. 1992, 10, 1158-1168.
17. Hutchins, J.T.; Deans, R.J.; Mitchell, M.S.; Uchiyama, C.; Kan-Mitchell, J. Novel Gene Sequences Expressed by Human Melanoma Cells Identified by Molecular Subtraction. Cancer Res. 1991, 51, 1418-1425.
18. Weiler, S.R.; Taylor, S.M.; Deans, R.J.; Kan-Mitchell, J.; Mitchell, M.S.; Trent, J.M. Assignment of a Human Melanoma Associated Gene MG50 (D2S448) to Chromosome 2p25.3 by Fluorescence In Situ Hybridization. Genomics 1994, 22, 243-244.
19. Mitchell, M.S.; Kan-Mitchell, J.; Minev, B.; Edman, C.; Deans, R.J. A Novel Melanoma Gene (MG50) Encoding the Interleukin I Receptor Antagonist and Six Epitopes Recognized by Human Cytolytic T Lymphocytes. Cancer Res. 2000, 60, 6448-6456.
20. Nestle, F.O.; Alijagic, S.; Gilliet, M.; Sun, M.; Grabbe, S.; Dummer, R. ; Burg, G.; Schadendorf, D. Vaccination of Melanoma Patients with Peptide-or Tumor Lysate-Pulsed Dendritic Cells. Nat. Med. 1998, 4, 328-332.
21. Sosman, J.A.; Unger, J.M.; Liu, P.Y.; Flaherty, L.E.; Park, M.S.; Keupf, R.A.; Thompson, J.A.; Terasaki, P.I.; Sondak, V.K. Adjuvant Immunotherapy of Resected, Intermediate Thickness Node-Negative Melanoma with an Allogeneic Tumor Vaccine: Impact on HLA Class 1 Antigen Expression on Outcome. Clin. Oncol. 2002, 20, 2067-2075.